EUROATLANTIC-AIRWAYS
17.4.2024 09:01:28 CEST | Business Wire | Press release
euroAtlantic Airways – Transportes Aereos S.A. (“euroAtlantic”, “EAA” or “the Company”), the Portuguese aircraft wet-leasing and charter business, today announces that Stewart Higginson has been appointed CEO and Chair of euroAtlantic and will be joined by the highly experienced management team of Mário Alvim, Lourenço Gomes and João Nunes, who will complete the Board.
Alongside the Board changes, Njord I-Jet Aviation S.A.R.L ("Njord I-Jet"), which owns a controlling interest in EAA, has committed further funding to the Company, demonstrating Njord I-Jet’s confidence in the positive outlook for the business and positioning EAA for growth as it enters the next important phase in its development. The management team’s focus will be on optimising performance improvements and expanding the Company’s current fleet of five Boeing aircraft to meet demand and improving its market-leading ACMI and charter services.
Stewart has deep experience of delivering operational performance improvements in companies across multiple sectors. He has been an Operating Partner with Njord Partners since February 2015, during which time he has held a number of key leadership roles including CEO of Geoquip Marine and CEO of Nuova Deroma, and has held a number of board roles as both a director and Chair. Stewart has received multiple awards and nominations for his instrumental roles in corporate restructurings and turnarounds, including International Turnaround of the Year for DeepOcean in 2012, and for Solidal in 2020. Stewart was a Director at Alix Partners for nine years and is a member of the UK Institute for Turnaround.
Mário, Lourenço and João collectively have more than 40 years’ experience at euroAtlantic and c. 100 years of experience in the aviation industry. Mário is euroAtlantic’s Chief Pilot and has been at the Company since its founding year (1993). He started his career at Air Atlantis. Lourenço is Chief Operations Officer. He joined the Company in March 2016, having previously held management positions at TAP. He started his career as a pilot for Portugalia Airlines, TAP Portugal and Emirates. João rejoined euroAtlantic in March 2023, after having previously worked for euroAtlantic between 2004 and 2008 and holds the role of Accountable Manager. His 25+ year career in aviation includes experienced roles at TAP, Netjets and JetCapitalAviation, where he was Airworthiness Manager and Deputy Accountable Manager.
Njord I-Jet is wholly owned by funds managed by Njord Partners LLP, a long-term investor in the Western European middle-market with significant and proven expertise in successful turnarounds. Njord Partners has assets under management in excess of €1 billion, providing capital solutions and actively facilitating strategic and operational enhancements within its portfolio companies to drive value for all stakeholders.
Stewart Higginson, euroAtlantic CEO and Chair, commented: “I am delighted to be joining euroAtlantic, where I look forward to working with the new Board to drive the next phase of euroAtlantic’s growth and deliver a world-class ACMI and charter solutions business.”
Jakob Kjellberg, Co-Founder and Co-Portfolio Manager at Njord Partners, said: “We are excited about the future prospects of well capitalized EAA under new leadership. The Company couldn’t have anyone better than Stewart and the team to lead it through its ongoing transformation and deliver high quality, cost effective and flexible services to our valued customers. Stewart’s experience in optimising operations and performance is second-to-none and we know the business will thrive with him in this new role.”
About euroAtlantic Airways
euroAtlantic Airways is a Portuguese airline specializing in ACMI and charter solutions, operating a diverse fleet of aircraft. Headquartered in Carnaxide and based at Lisbon Airport, it offers charter services, wet-lease, and Ad-Hoc flights across the globe, and has served 719 Airports in 176 countries in 30 years of operations. euroAtlantic Airways was acquired a consortium including Njord Partners, in November 2019.
To find out more visit: https://www.euroatlantic.pt/en/quem-somos/
About Njord Partners
Njord Partners is a European special situations investment manager and provider of long-term flexible capital solutions, primarily to family-owned businesses. Established in 2013, Njord Partners has invested in 24 businesses and manages capital in excess of €1 billion. The Njord team has led turnarounds of over 25 companies located in 9 different jurisdictions, spanning 8 separate industries.
To find out more visit: https://njordpartners.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417583477/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release
Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S
Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 13:00:00 CEST | Press release
Stablecoin settlement pilot sees record growth 50% quarter over quarter, reaching $7B run rate. Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means o
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom